# Tramadol induced hypoxia signaling and paraptosis-like cell death in breast cancer cells via HIF-1α and ATF4 dependent pathways

**Authors:** Zih-Syuan Wu, Shih-Ming Huang, Yi-Hsuan Huang

PMC · DOI: 10.1080/13510002.2025.2588866 · 2026-01-12

## TL;DR

Tramadol, a painkiller, kills breast cancer cells by triggering hypoxia and paraptosis-like cell death through HIF-1α and ATF4 pathways.

## Contribution

The study reveals a novel mechanism of tramadol-induced cell death in breast cancer via HIF-1α and ATF4 pathways.

## Key findings

- Tramadol stabilizes HIF-1α and activates hypoxia-responsive genes under normoxic conditions.
- Tramadol causes ER stress and mitochondrial dysfunction, leading to paraptosis-like cell death.
- Knockout of HIF-1α or ATF4 reduces tramadol's cytotoxic effects, confirming their essential roles.

## Abstract

Tramadol, a clinically approved analgesic widely used for managing postoperative pain, has recently been shown to possess anticancer properties in several tumor models, especially in breast cancer. In this study, we explored the intricate molecular mechanisms by which tramadol induces cytotoxicity in breast cancer cell lines.

Two invasive ductal carcinoma lines MCF-7 and MDA-MB-231 were used to verify the molecular cytotoxicity of tramadol using cell viability analysis, flow cytometry analysis, real-time polymerase chain reaction, western blotting, Seahorse biogenetic, and transmission electron microscopy analyses.

Our findings demonstrate that tramadol induces the normoxic stabilization and nuclear translocation of hypoxia-inducible factor- 1 alpha (HIF-1α) to activate hypoxia responsive genes. Concurrently, tramadol triggers endoplasmic reticulum (ER) stress and activates the p-eIF2α/ATF4/CHOP signaling axis, leading to the generation of reactive oxygen species, impaired autophagy, mitochondrial dysfunction, including mitochondrial membrane depolarization and the decline of ATP production, cytoplasmic vacuolization, and lipid droplet accumulation which is characteristics of paraptosis-like cell death. Notably, the knockout of HIF-1α or ATF4 significantly reduced tramadol-induced cytotoxicity, highlighting their crucial roles in mediating these cellular responses.

Tramadol induced breast cancer cell death via paraptosis which highlights its therapeutic potential in targeting resistant cancer subtypes such as triple-negative breast cancer.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], ATF4 (activating transcription factor 4) [NCBI Gene 468], DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649]
- **Chemicals:** Tramadol (PubChem CID 19472)
- **Diseases:** breast cancer (MONDO:0004989), triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, FLVCR1 (FLVCR choline and heme transporter 1) [NCBI Gene 28982] {aka AXPC1, FLVCR, MFSD7B, NEDMISH, PCA, PCARP}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, JDP2 (Jun dimerization protein 2) [NCBI Gene 122953] {aka JUNDM2}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, ATF3 (activating transcription factor 3) [NCBI Gene 467], HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, BHLHE40 (basic helix-loop-helix family member e40) [NCBI Gene 8553] {aka BHLHB2, Clast5, DEC1, HLHB2, SHARP-2, SHARP2}, CHAC1 (ChaC glutathione specific gamma-glutamylcyclotransferase 1) [NCBI Gene 79094], GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480] {aka CD221, IGFIR, IGFR, JTK13}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, TXNRD1 (thioredoxin reductase 1) [NCBI Gene 7296] {aka GRIM-12, TR, TR1, TRXR1, TXNR, TXNR1}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, ALG2 (ALG2 alpha-1,3/1,6-mannosyltransferase) [NCBI Gene 85365] {aka CDG1I, CDGIi, CMS14, CMSTA3, NET38, hALPG2}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** mitochondrial (MESH:D028361), non-small-cell lung cancer (MESH:D002289), head and neck squamous cell carcinoma (MESH:D000077195), respiratory depression (MESH:D012131), Cancer (MESH:D009369), hepatocellular carcinoma (MESH:D006528), chronic pain (MESH:D059350), hypoxic (MESH:D002534), Cytotoxicity (MESH:D064420), acute pain (MESH:D059787), Lentivirus infection (MESH:D016180), invasive ductal breast carcinoma (MESH:D018270), bone metastasis (MESH:D009362), invasive ductal carcinoma (MESH:D044584), postoperative pain (MESH:D010149), Hypoxia (MESH:D000860), oncogenes (MESH:D000074723), PCD (MESH:D003643), multidrug resistance (MESH:D018088), pain (MESH:D010146), Acute and chronic inflammation (MESH:D007249), endometrial cancer (MESH:D016889), TNBC (MESH:D064726), Breast cancer (MESH:D001943)
- **Chemicals:** fusaric acid (MESH:D005669), TRIzol (MESH:C411644), calcium (MESH:D002118), Lipid (MESH:D008055), NO (MESH:D009614), SDS (MESH:D012967), EPON 812 (MESH:C004875), polybrene (MESH:D006583), glutaraldehyde (MESH:D005976), DAPI (MESH:C007293), JC-1 (MESH:C068624), amino acids (MESH:D000596), propylene oxide (MESH:C009068), L-glutamine (MESH:D005973), sorafenib (MESH:D000077157), A8097 (-), MitoSOX Red (MESH:C000597839), paclitaxel (MESH:D017239), PX-478 (MESH:C492908), Puromycin (MESH:D011691), doxorubicin (MESH:D004317), antimycin A (MESH:D000968), metal (MESH:D008670), penicillin (MESH:D010406), 2',7-dichlorofluorescein diacetate (MESH:C029569), Triton X-100 (MESH:D017830), FCCP (MESH:D002259), paraformaldehyde (MESH:C003043), Tramadol (MESH:D014147), tamoxifen (MESH:D013629), ethanol (MESH:D000431), streptomycin (MESH:D013307), sodium bicarbonate (MESH:D017693), oxygen (MESH:D010100), M1 (MESH:C400939), cisplatin (MESH:D002945), F12 (MESH:C007782), Poly(A) (MESH:D011061), N-acetylcysteine (MESH:D000111), Z-VAD-FMK (MESH:C096713), ATP (MESH:D000255), PVDF (MESH:C024865), uranyl acetate (MESH:C005460), rotenone (MESH:D012402), oligomycin (MESH:D009840), proton (MESH:D011522), O-desmethyltramadol (MESH:C080580), ROS (MESH:D017382), CO2 (MESH:D002245), MTT (MESH:C070243), AO (MESH:D000165), PBS (MESH:D007854), serotonin (MESH:D012701), T-A (MESH:D013635), BODIPY 493/503 (MESH:C527198), naloxone (MESH:D009270), noradrenaline (MESH:D009638), ferrostatin-1 (MESH:C573944), morphine (MESH:D009020), CHX (MESH:D003513)
- **Species:** Moloney murine leukemia virus (no rank) [taxon 11801], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), BCRC-60436 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_RV99), HTB-26 — Mus musculus (Mouse), Hybridoma (CVCL_A8FQ), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), TransIT-LT1 — Homo sapiens (Human), Lung lymphangioleiomyomatosis, Finite cell line (CVCL_8891), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), MCF-10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), BT474 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0179)

## Figures

20 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12798667/full.md

---
Source: https://tomesphere.com/paper/PMC12798667